Hologram Quantitative Structure-Activity Relationships Study of N-Phenyl-N'-{4-(4-quinolyloxy)phenyl} Urea Derivatives as VEGFR-2 Tyrosine Kinase Inhibitors |
Keretsu, Seketoulie
(Department of Biomedical Sciences, College of Medicine, Chosun University)
Balasubramanian, Pavithra K. (Department of Biomedical Sciences, College of Medicine, Chosun University) Bhujbal, Swapnil P. (Department of Biomedical Sciences, College of Medicine, Chosun University) Cho, Seung Joo (Department of Biomedical Sciences, College of Medicine, Chosun University) |
1 | G. Bold, K.-H. Altmann, J. Frei, M. Lang, P. W. Manley, P. Traxler, B. Wietfeld, J. Bruggen, E. Buchdunger, R. Cozens, S. Ferrari, P. Furet, F. Hofmann, G. Martiny-Baron, J. Mestan, J. Rosel, M. Sills, D. Stover, F. Acemoglu, E. Boss, R. Emmenegger, L. Lasser, E. Masso, R. Roth, C. Schlachter, W. Vetterli, D. Wyss, and J. M. Wood, "New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis", J. Med. Chem., Vol. 43, pp. 2310-2323, 2000. DOI |
2 | N. A. G. Lankheet, M. J. X. Hillebrand, H. Rosing, J. H. Schellens, J. H. Beijnen, and A. D. R. Huitema, "Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry", Biomed. Chromatogr., Vol. 27, pp. 466-476, 2013. DOI |
3 | T. K. Choueiri, F. A. Schutz, Y. Je, J. E. Rosenberg, and J. Bellmunt, "Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials", J. Clin. Oncol., Vol. 28, pp. 2280-2285, 2010. DOI |
4 | H. X. Chen and J. N. Cleck, "Adverse effects of anticancer agents that target the VEGF pathway", Nat. Rev. Clin. Oncology., Vol. 6, pp. 465-477, 2009. DOI |
5 | T. Kamba and D. M. McDonald, "Mechanisms of adverse effects of anti-VEGF therapy for cancer", Br. J. cancer, Vol. 96, pp. 1788-1795, 2007. DOI |
6 | J. Verma, V. M. Khedkar, and E. C. Coutinho, "3DQSAR in drug design-a review", Curr. Top. Med. Chem, Vol. 10, pp. 95-115, 2010. DOI |
7 | A. Z. Dudek, T. Arodz, and J. Galvez, "Computational methods in developing quantitative structureactivity relationships (QSAR): a review", Comb. Chem. high throughput screen., Vol. 9, pp. 213-228, 2006. DOI |
8 | H. Zeng and H. Zhang, "Combined 3D-QSAR modeling and molecular docking study on 1, 4-dihydroindeno [1, 2-c] pyrazoles as VEGFR-2 kinase inhibitors", J. Mol. Graph. Model., Vol. 29, pp. 54-71, 2010. DOI |
9 | M. M. Neaz, F. A. Pasha, M. Muddassar, S. H. Lee, T. Sim, J.-M. Hah, and S. J. Cho, "Pharmacophore based 3D-QSAR study of VEGFR-2 inhibitors", Med. Chem. Res., Vol. 18, pp. 127-142, 2009. DOI |
10 | C. Munoz, F. Adasme, J. H. Alzate-Morales, A. Vergara-Jaque, T. Kniess, and J. Caballero, "Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations", J. Mol. Graph. Model., Vol. 32, pp. 39-48, 2012. DOI |
11 | K. Kubo, T. Shimizu, S.-I. Ohyama, H. Murooka, A. Iwai, K. Nakamura, K. Hasegawa, Y. Kobayashi, N. Takahashi, K. Takahashi, S. Kato, T. Izawa, and T. Isoe, "Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of n-phenyl-n '-{4-(4-quinolyloxy) phenyl} ureas", J. Med. Chem., Vol. 48, pp. 1359-1366, 2005. DOI |
12 | K. J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, and N. Ferrara, "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo", Nature, Vol. 362, pp. 841-844, 1993. DOI |
13 | J. Folkman, "Anti-angiogenesis: new concept for therapy of solid tumors", Ann. Surg., Vol. 175, pp. 409-416, 1972. DOI |
14 | G. Bergers, K. Javaherian, K.-M. Lo, J. Folkman, and D. Hanahan, "Effects of angiogenesis inhibitors on multistage carcinogenesis in mice", Science, Vol. 284, pp. 808-812, 1999. DOI |
15 | T.-P. D. Fan, R. Jagger, and R. Bicknell, "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy", Trends Pharmacol. Sci., Vol. 16, pp. 57-66, 1995. DOI |
16 | W. Kolch, G. Martiny-Baron, A. Kieser, and D. Marme, "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis", Breast Cancer Res. Treat., Vol. 36, pp. 139-155, 1995. DOI |
17 | W. P. Leenders, "Targetting VEGF in anti-angiogenic and anti-tumour therapy: Where are we now?", Int. J. Exp. Pathol., Vol. 79, pp. 339-346, 1998. |
18 | C. R. Rodrigues, T. M. Flaherty, C. Springer, J. H. McKerrow, and F. E. Cohen, "CoMFA and HQSAR of acylhydrazide cruzain inhibitors", Bioorg. Med. Chem. Lett., Vol. 12, pp. 1537-1541, 2002. DOI |
19 | M. Clark, R. D. Cramer, and N. Van Opdenbosch, "Validation of the general purpose Tripos 5.2 force field", J. Comput. Chem., Vol. 10, pp. 982-1012, 1989. DOI |
20 | M. A. Avery, M. Alvim-Gaston, C. R. Rodrigues, E. J. Barreiro, F. E. Cohen, Y. A. Sabnis, and J. R. Woolfrey, "Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies", J. Med. Chem., Vol. 45, pp. 292-303, 2002. DOI |
21 | W. Zhu, G. Chen, L. Hu, X. Luo, C. Gui, C. Luo, C. M. Puah, K. Chen, and H. Jiang, "QSAR analyses on ginkgolides and their analogues using CoMFA, CoMSIA, and HQSAR", Bioorg. Med. Chem., Vol. 13, pp. 313-322, 2005. DOI |
22 | S. P. Bhujbal, S. Keretsu, and S. J. Cho, "HQSAR study on substituted 1H-pyrazolo [3, 4-b] pyridines derivatives as FGFR kinase antagonists", J. Chosun Natural Sci., Vol. 10, pp. 85-94, 2017. |
23 | V. G. Ugale, H. M. Patel, and S. J. Surana, "Molecular modeling studies of quinoline derivatives as VEGFR-2 tyrosine kinase inhibitors using pharmacophore based 3D QSAR and docking approach", Arabian Journal of Chemistry, Vol. 10, pp. S1980-S2003, 2017. DOI |
24 | T. A. T. Fong, L. K. Shawver, L. Sun, C. Tang, H. App, T. J. Powell, Y. H. Kim, R. Schreck, X. Wang, W. Risau, A. Ullrich, K. P. Hirth, and G. McMahon, "SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types", Cancer res, Vol. 59, pp. 99-106, 1999. |
25 | L. Sun, N. Tran, F. Tang, H. App, P. Hirth, G. McMahon, and C. Tang, "Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases", J. Med. Chem., Vol. 41, pp. 2588-2603, 1998. DOI |
26 | L. Sun, N. Tran, C. Liang, F. Tang, A. Rice, R. Schreck, K. Waltz, L. K. Shawver, G. McMahon, and C. Tang, "Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl) methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases", J. Med. Chem., Vol. 42, pp. 5120-5130, 1999. DOI |
27 | L. F. Hennequin, E. S. Stokes, A. P. Thomas, C. Johnstone, P. A. Ple, D. J. Ogilvie, M. Dukes, S. R. Wedge, J. Kendrew, and J. O. Curwen, "Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors", J. Med. Chem., Vol. 45, pp. 1300-1312, 2002. DOI |